Understanding how protein balance affects treatment resistance in prostate cancer
Dissecting the Role of Proteostasis in Anti-Androgen Resistant Prostate Cancer
This study is looking into why some prostate cancer cells don't respond to common treatments and how the balance of certain proteins in those cells might be the key, with the goal of finding better ways to help patients who are facing treatment resistance.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California at Davis NIH-funded |
| Lab location | 1 site (Davis, United States) |
| Project ID | NIH-10930002 on NIH RePORTER |
What this research studies
This research investigates the mechanisms behind treatment resistance in prostate cancer, particularly focusing on how protein balance, or proteostasis, plays a role. The study aims to identify how certain proteins become stabilized in cancer cells that resist anti-androgen therapies, which are commonly used to treat advanced prostate cancer. By examining the pathways involved in protein degradation and stabilization, researchers hope to uncover new strategies to overcome resistance and improve treatment outcomes for patients. The approach includes analyzing cancer cell behavior and the effects of small molecule inhibitors on protein interactions.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with advanced prostate cancer who have developed resistance to anti-androgen therapies.
Not a fit: Patients with early-stage prostate cancer or those who have not undergone anti-androgen treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with anti-androgen resistant prostate cancer.
How similar studies have performed: Previous research has shown promising results in targeting proteostasis mechanisms in cancer, indicating that this approach may lead to significant advancements in treatment.
Where this research is happening
Davis, United States
- University of California at Davis — Davis, United States (Active)
Researchers
- Principal investigator: Liu, Chengfei — University of California at Davis
- Study coordinator: Liu, Chengfei
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.